

Frank van Leth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5024566/publications.pdf>

Version: 2024-02-01

118
papers

4,402
citations

186265

28
h-index

114465

63
g-index

122
all docs

122
docs citations

122
times ranked

4729
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. <i>Lancet</i> , The, 2004, 363, 1253-1263.	13.7	665
2	Lipid Profiles in HIV-1 Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?. <i>Journal of Infectious Diseases</i> , 2004, 189, 1056-1074.	4.0	318
3	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2014, 44, 23-63.	6.7	256
4	Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. <i>PLoS Medicine</i> , 2004, 1, e19.	8.4	220
5	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. <i>Aids</i> , 2001, 15, 2407-2414.	2.2	212
6	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1168-1176.	5.6	196
7	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. <i>Aids</i> , 2003, 17, 987-999.	2.2	151
8	Measuring tuberculosis burden, trends, and the impact of control programmes. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 233-243.	9.1	149
9	Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2337-2353.	3.0	143
10	Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?. <i>Antiviral Therapy</i> , 2005, 10, 489-498.	1.0	135
11	Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study. <i>Antiviral Therapy</i> , 2005, 10, 145-155.	1.0	80
12	Multidrug-Resistant Tuberculosis in Europe, 2010-2011. <i>Emerging Infectious Diseases</i> , 2015, 21, 409-416.	4.3	75
13	Treatment Outcomes in Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2016, 375, 1103-1105.	27.0	73
14	Prevalence of tuberculous infection and incidence of tuberculosis; a re-assessment of the Styblo rule. <i>Bulletin of the World Health Organization</i> , 2008, 86, 20-26.	3.3	71
15	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1029-1031.	5.6	71
16	Incidence and Predictors of Mortality and the Effect of Tuberculosis Immune Reconstitution Inflammatory Syndrome in a Cohort of TB/HIV Patients Commencing Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 32-37.	2.1	61
17	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. <i>Nature Medicine</i> , 2020, 26, 1941-1949.	30.7	58
18	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	1.2	55

#	ARTICLE	IF	CITATIONS
19	Epidemiology of Tuberculosis in an Urban Slum of Dhaka City, Bangladesh. <i>PLoS ONE</i> , 2013, 8, e77721.	2.5	47
20	Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. <i>European Respiratory Journal</i> , 2015, 45, 1081-1088.	6.7	44
21	Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort. <i>Pediatrics</i> , 2006, 117, e528-e536.	2.1	37
22	Comparison of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis. <i>BMC Research Notes</i> , 2013, 6, 291.	1.4	36
23	Adherence to Tuberculosis Therapy among Patients Receiving Home-Based Directly Observed Treatment: Evidence from the United Republic of Tanzania. <i>PLoS ONE</i> , 2012, 7, e51828.	2.5	34
24	Highly Active Antiretroviral Therapy-Induced Lipodystrophy Has Minor Effects on Human Immunodeficiency Virus-Induced Changes in Lipolysis, but Normalizes Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5066-5071.	3.6	33
25	Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naïve HIV-1 patients. <i>Aids</i> , 2004, 18, 1925-1931.	2.2	33
26	Pharmacy-based hypertension care employing mHealth in Lagos, Nigeria – a mixed methods feasibility study. <i>BMC Health Services Research</i> , 2018, 18, 934.	2.2	33
27	Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. <i>European Respiratory Journal</i> , 2012, 40, 1443-1449.	6.7	32
28	Socio Economic Position in TB Prevalence and Access to Services: Results from a Population Prevalence Survey and a Facility-Based Survey in Bangladesh. <i>PLoS ONE</i> , 2012, 7, e44980.	2.5	32
29	Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. <i>HIV Medicine</i> , 2004, 5, 74-81.	2.2	31
30	Healthcare Workers' Challenges in the Implementation of Tuberculosis Infection Prevention and Control Measures in Mozambique. <i>PLoS ONE</i> , 2014, 9, e114364.	2.5	31
31	Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 640-646.	1.2	30
32	Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1014-1021.	1.2	29
33	Epstein-Barr Virus Infects B and Non-B Lymphocytes in HIV-1 Infected Children and Adolescents. <i>Journal of Infectious Diseases</i> , 2006, 194, 1323-1330.	4.0	28
34	Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 26-34.	2.1	28
35	Numbers needed to treat to prevent tuberculosis. <i>European Respiratory Journal</i> , 2015, 46, 1836-1838.	6.7	28
36	Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw578.	3.0	27

#	ARTICLE	IF	CITATIONS
37	Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 379-386.	5.6	27
38	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , 2021, 58, 2003492.	6.7	27
39	Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study. <i>HIV Clinical Trials</i> , 2005, 6, 254-261.	2.0	26
40	Prevalence of smear-positive tuberculosis in persons aged ≥ 15 years in Bangladesh: results from a national survey, 2007–2009. <i>Epidemiology and Infection</i> , 2012, 140, 1018-1027.	2.1	26
41	Factors associated with poor knowledge among adults on tuberculosis in Bangladesh: results from a nationwide survey. <i>Journal of Health, Population and Nutrition</i> , 2015, 34, 2.	2.0	25
42	Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study. <i>BMC Medicine</i> , 2009, 7, 80.	5.5	24
43	Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. <i>HIV Medicine</i> , 2012, 13, 337-344.	2.2	23
44	Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1524-1527.	1.2	23
45	Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz. <i>Antiviral Therapy</i> , 2004, 9, 721-728.	1.0	23
46	Evaluation of the Genotype [®] MTBDR _{plus} assay as a tool for drug resistance surveys. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 959-965.	1.2	20
47	Coverage and yield of tuberculosis contact investigations in the Netherlands. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1630-1637.	1.2	20
48	Implementation of tuberculosis infection prevention and control in Mozambican health care facilities. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 44-49.	1.2	20
49	Health-seeking norms for tuberculosis symptoms in southern Angola: implications for behaviour change communications. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 943-948.	1.2	17
50	Treatment outcomes of MDR-TB and HIV co-infection in Europe. <i>European Respiratory Journal</i> , 2017, 49, 1602363.	6.7	17
51	Relapse-free cure from multidrug-resistant tuberculosis in Germany. <i>European Respiratory Journal</i> , 2018, 51, 1702122.	6.7	17
52	TB diagnostic process management of patients in a referral hospital in Mozambique in comparison with the 2007 WHO recommendations for the diagnosis of smear-negative pulmonary TB and extrapulmonary TB. <i>International Health</i> , 2013, 5, 302-308.	2.0	16
53	Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. <i>Infectious Diseases</i> , 2017, 49, 161-169.	2.8	16
54	Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8 ⁺ CD45RA ⁺ CD27 ⁺ T cells in HIV-1-infected children. <i>Aids</i> , 2005, 19, 1025-1034.	2.2	15

#	ARTICLE	IF	CITATIONS
55	Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design. BMC Public Health, 2016, 16, 915.	2.9	15
56	Antimicrobial resistance among uropathogens in the Asia-Pacific region: a systematic review. JAC-Antimicrobial Resistance, 2021, 3, dlab003.	2.1	15
57	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59, 2200388.	6.7	15
58	Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery. Tropical Medicine and International Health, 2012, 17, 1527-1533.	2.3	14
59	Sensitivity of point-of-care testing C reactive protein and procalcitonin to diagnose urinary tract infections in Dutch nursing homes: PROGRESS study protocol. BMJ Open, 2019, 9, e031269.	1.9	14
60	Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Medicine, 2006, 7, 347-350.	2.2	13
61	Multidrug Resistance Among New Tuberculosis Cases. Epidemiology, 2012, 23, 293-300.	2.7	13
62	Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study.. BMC Public Health, 2012, 12, 674.	2.9	13
63	Projection of the number of patients with tuberculosis in the Netherlands in 2030. European Journal of Public Health, 2009, 19, 424-427.	0.3	12
64	Missed opportunities in tuberculosis control in The Netherlands due to prioritization of contact investigations. European Journal of Public Health, 2012, 22, 177-182.	0.3	12
65	Tuberculin survey in Bangladesh, 2007-2009: prevalence of tuberculous infection and implications for TB control. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1267-1272.	1.2	12
66	Care seeking in tuberculosis: results from a countrywide cluster randomised survey in Bangladesh. BMJ Open, 2014, 4, e004766.	1.9	12
67	Rethinking Antimicrobial Resistance Surveillance: A Role for Lot Quality Assurance Sampling. American Journal of Epidemiology, 2019, 188, 734-742.	3.4	12
68	Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1265-1271.	1.4	11
69	TB-HIV co-infection in the Netherlands: estimating prevalence and under-reporting in national registration databases using a capture-recapture analysis. Journal of Epidemiology and Community Health, 2016, 70, 556-560.	3.7	11
70	Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1222-1224.	5.6	11
71	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respiratory Medicine, 2018, 6, 246-248.	10.7	11
72	Viral Load and Risk of Tuberculosis in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e51-e53.	2.1	10

#	ARTICLE	IF	CITATIONS
73	Sensitivity of C-Reactive Protein and Procalcitonin Measured by Point-of-Care Tests to Diagnose Urinary Tract Infections in Nursing Home Residents: A Cross-Sectional Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3867-e3875.	5.8	10
74	Predictive Value of the Tuberculin Skin Test among Newly Arriving Immigrants. <i>PLoS ONE</i> , 2013, 8, e60130.	2.5	10
75	Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. <i>Antiviral Therapy</i> , 2004, 9, 721-8.	1.0	10
76	Implementation of a national anti-tuberculosis drug resistance survey in Tanzania. <i>BMC Public Health</i> , 2008, 8, 427.	2.9	9
77	Predictive value of the urinary dipstick test in the management of patients with urinary tract infection-associated symptoms in primary care in Indonesia: a cross-sectional study. <i>BMJ Open</i> , 2018, 8, e023051.	1.9	9
78	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. <i>European Respiratory Journal</i> , 2019, 53, 1802089.	6.7	9
79	Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia. <i>PLoS ONE</i> , 2020, 15, e0230489.	2.5	9
80	Adherence by Dutch Public Health Nurses to the National Guidelines for Tuberculosis Contact Investigation. <i>PLoS ONE</i> , 2012, 7, e49649.	2.5	9
81	Assessment of patient preference in allocation and observation of anti-tuberculosis medication in three districts in Tanzania. <i>Patient Preference and Adherence</i> , 2008, 2, 1-6.	1.8	9
82	Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1326-1333.	1.2	8
83	Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 531-536.	1.2	8
84	Treatment responses in multidrug-resistant tuberculosis in Germany. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 399-406.	1.2	8
85	Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future. <i>Respiration</i> , 2021, 100, 843-852.	2.6	8
86	Changes in disclosure, adherence and healthcare interactions after the introduction of immediate ART initiation: an analysis of patient experiences in Swaziland. <i>Tropical Medicine and International Health</i> , 2019, 24, 563-570.	2.3	7
87	Health workersâ€™ performance in the implementation of Patient Centred Tuberculosis Treatment (PCT) strategy under programmatic conditions in Tanzania: a cross sectional study. <i>BMC Health Services Research</i> , 2013, 13, 101.	2.2	6
88	Mass drug administrations with dihydroartemisinin-piperazine and single low dose primaquine to eliminate <i>Plasmodium falciparum</i> have only a transient impact on <i>Plasmodium vivax</i> : Findings from randomised controlled trials. <i>PLoS ONE</i> , 2020, 15, e0228190.	2.5	6
89	Use of Composite End Points to Measure Clinical Events. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1456-b-1457.	7.4	6
90	Are routine tuberculosis programme data suitable to report on antiretroviral therapy use of HIV-infected tuberculosis patients?. <i>BMC Research Notes</i> , 2013, 6, 23.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Validation of indirect tuberculosis treatment adherence measures in a resource-constrained setting. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 804-809.	1.2	5
92	Rapid assessment of antimicrobial resistance prevalence using a Lot Quality Assurance sampling approach. <i>Future Microbiology</i> , 2017, 12, 369-377.	2.0	5
93	Embracing the challenges of HIV-TB co-infection in children [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 379-379.	1.2	4
94	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of <i>Plasmodium vivax</i> infections: a randomized, controlled trial in Lao PDR. <i>Malaria Journal</i> , 2020, 19, 4.	2.3	4
95	Appropriateness of diagnosis and antibiotic use in sepsis patients admitted to a tertiary hospital in Indonesia. <i>Postgraduate Medicine</i> , 2020, 133, 1-6.	2.0	4
96	Bridging the TB data gap: <i>in silico</i> extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data. <i>PeerJ</i> , 2019, 7, e7564.	2.0	4
97	Unbiased antimicrobial resistance prevalence estimates through population-based surveillance. <i>Clinical Microbiology and Infection</i> , 2023, 29, 429-433.	6.0	4
98	Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. <i>Antiviral Therapy</i> , 2013, 18, 615-622.	1.0	3
99	Design of pragmatic trials of tuberculosis interventions. <i>Lancet, The</i> , 2014, 383, 213-214.	13.7	3
100	Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 296-300.	2.1	3
101	Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model. <i>BMC Infectious Diseases</i> , 2022, 22, 346.	2.9	3
102	Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens. <i>Aids</i> , 2005, 19, 1722-1723.	2.2	2
103	The effect of tuberculosis and antiretroviral treatment on CD4+ cell count response in HIV-positive tuberculosis patients in Mozambique. <i>BMC Public Health</i> , 2012, 12, 670.	2.9	2
104	Latent tuberculosis infection as a target for tuberculosis control. <i>Future Microbiology</i> , 2015, 10, 905-908.	2.0	2
105	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	5.6	2
106	An easy tool to assess ventilation in health facilities as part of air-borne transmission prevention: a cross-sectional survey from Uganda. <i>BMC Infectious Diseases</i> , 2017, 17, 325.	2.9	2
107	Contact tracing in low-incidence tuberculosis settings. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1566-1566.	1.2	1
108	Testing for LTBI: more of the same or a step forward?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 591-591.	1.2	1

#	ARTICLE	IF	CITATIONS
109	Epidemiological Surveys Embedded in Technical Assistance to Tuberculosis Control Programmes. The Open Infectious Diseases Journal, 2013, 7, 65-71.	0.6	1
110	Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: Response. BMC Medical Research Methodology, 2007, 7, 14.	3.1	0
111	Antiretroviral therapy and tuberculosis: does the regimen matter?. Expert Review of Anti-Infective Therapy, 2014, 12, 5-7.	4.4	0
112	Pathogen-free diagnosis of tuberculosis. Lancet Infectious Diseases, The, 2021, 21, 1066.	9.1	0
113	Clinical Reasoning Underlying Guideline Nonadherence in Urinary Tract Infections in Nursing Homes. Journal of the American Medical Directors Association, 2022, 23, 896-898.	2.5	0
114	Editorial - Technical Assistance to Tuberculosis Control Programmes as a Platform for Infectious Disease Research. The Open Infectious Diseases Journal, 2013, 7, 21-22.	0.6	0
115	Title is missing!. , 2020, 15, e0230489.		0
116	Title is missing!. , 2020, 15, e0230489.		0
117	Title is missing!. , 2020, 15, e0230489.		0
118	Title is missing!. , 2020, 15, e0230489.		0